News

Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SoFi’s Liz Thomas breaks down why the S&P still has room to run — and the sectors retail investors should be buying now.

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while raising its full-year sales outlook. The medical device company posted adjusted earnings per share of $0.86, ahead of the $0.83 consensus...

KLA's fiscal Q4 earnings beat estimates as AI infrastructure, foundry/logic and process control demand lift revenues 15.2% and strengthen its outlook.

Coke just raised guidance twice this year while Pepsi watches its biggest snack unit stumble, yet one of these stocks may be a far more compelling buy heading into the second half of 2026.

Norfolk Southern (NSC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Comfort Systems (FIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ODFL's Q2 earnings rise 32.3% as stronger yield, cost discipline and margin gains offset continued freight-volume pressure.

Meta Platforms Inc (NASDAQ:META, XETRA:FB2A, SIX:FB) is expected to post second-quarter results above Wall Street expectations, with analysts pointing to healthy advertising demand and early returns from artificial intelligence investment even as investors press the company for clearer evidence...

NXPI posts Q2 earnings and revenue beats as automotive, industrial and AI data center demand lift growth, with strong Q3 guidance adding momentum.

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

UNH's improving cost control, lower medical costs and higher 2026 outlook are boosting confidence as its profitability recovery gains traction.

Schwab renamed its crypto ETF around AI stock-picking software. Trump Media ranked second on the list that day.

Ram, Jeep, and Fiat parent company Stellantis reported decent first-half results on Thursday morning, but only reaffirmed its prior guidance. Investors clearly want more from CEO Antonio Filosa's turnaround plan.

The company reported a 557% annual increase in operating income in the second quarter.

Two trading sessions reached opposite conclusions about the same report. One of them had the better argument.

Centene (CNC) delivered a stronger-than-expected Q2, but investor attention shifted to management's

GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

JCI beats third-quarter estimates with double-digit organic growth in key markets and raises its fiscal 2026 outlook on strong operating momentum.

V posts Q3 earnings and revenue beats as cross-border volumes, spending trends and network activity drive double-digit growth.

Arch Capital beats Q2 earnings estimates as investment income offsets catastrophe pressure, despite lower premiums and underwriting profit.

IEX tops second-quarter estimates, posts record orders above $1 billion and raises its 2026 outlook as demand improved across key end markets.

Amazon has shed 6% in a week while sitting on the most aggressive capital spending in its history, yet Wall Street still sees a breakout coming. Here is what makes or breaks that case before July 30.

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

HUM's Q2 earnings top estimates as medical membership growth, premium gains and CenterWell strength lift results despite higher costs.

Skyworks Solutions tops fiscal Q3 estimates as Broad Markets growth, led by AI data center, offsets weaker revenues and margin pressure.

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.

SWK tops Q2 estimates and raises its 2026 outlook after stronger margins, cash generation and improved operating performance.

F's Q2 earnings beat as stronger pricing and product mix lifted EBIT, prompting higher 2026 profit and free cash flow guidance.

CrowdStrike stock is in focus on a bullish Loop Capital research note. Here’s why the firm remains positive on CRWD shares.